CIP
RXDX

Chartwell Investment Partners’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Chartwell Investment Partners’s Portfolio RXDX Stock Details RXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-9,408
Closed -$555K – 445
2022
Q3 		$555K Buy
+9,408
New +$430K 0.02% 381

Other funds holding RXDX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Chartwell Investment Partners's RXDX Position: Q4 2022 in Review

Chartwell Investment Partners sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q4 2022, closing a stake of 9,408 shares — an estimated $555K sold.

Chartwell Investment Partners first reported a position in RXDX in Q3 2022 and held it in 1 quarter. The position peaked at $555K in Q3 2022. 221 funds tracked by Wall St. Rank hold RXDX as of Q4 2022.

  • Chartwell Investment Partners reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Chartwell Investment Partners sold 9,408 Prometheus Biosciences, Inc. Common Stock shares in Q4 2022, an estimated $555K.
  • Chartwell Investment Partners first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Chartwell Investment Partners's Prometheus Biosciences, Inc. Common Stock position peaked at $555K in Q3 2022.
  • 221 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q4 2022.

Based on Chartwell Investment Partners's 13F filing for Q4 2022, filed 16 Feb 2023.